Laura Tadvalkar
Managing Director·RA Capital Management
Laura Tadvalkar is a Managing Director on RA Capital's Venture Team, where she works on new company creation and early-stage investments. She serves as a board director for Be Biopharma, Hemab, Hyku Biosciences, and Typewriter Therapeutics, and previously served on the board of Mariana Oncology before its acquisition by Novartis and as board chair of Aliada Therapeutics before its acquisition by AbbVie. Before RA Capital, she was a Principal at MP Healthcare Venture Management and a Consultant at Clarion Healthcare.
See the rest of Laura Tadvalkar's profile.
Deal history, investment focus, outreach angles and the rest of the background. One email, no password — we send a link and you land right back here.